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Nicotine dependence is a major cause of mortality and morbidity all over the world. Various medications have been tried to
treat nicotine dependence including nicotine replacement therapy, bupropion, and varenicline. A newer venture to nicotine
dependencetreatmentisanicotinevaccinewhichisyettogetfootstepsincommonpractice.Thepresentreviewassimilatesvarious
pharmacotherapeutic measures to address nicotine dependence. However, it is to be noted that psychological interventions, when
combined with pharmacotherapy, offer the greatest benefits to the patients.
1. Introduction
W o r l d w i d et h e r ea r en e a r l y1 . 2b i l l i o nu s e r so fn i c o t i n ea n d
tobacco products [1]. In India, the overall prevalence of
c u r r e n tt o b a c c ou s ef r o mt h eN H S D A A( N a t i o n a lH o u s e -
hold Survey of Drug and Alcohol Abuse) was 55.8% [2].
W orldwidetobaccousecausesmorethan5milliondeathsper
year, and if smoking prevalence continues to increase in the
developing world, the number of annual deaths attributable
to cigarette smoking will be more than 8 million by 2030
[1]. Eleven percent of deaths from ischemic heart disease, the
world’s leading killer, are attributable to tobacco use. More
than 70% of deaths from lung, trachea, and bronchus cancers
a r ea t t r i b u t a b l et ot o b a c c ou s e[ 3].
Across studies, it has been found that the morbidity
and mortality associated with tobacco use are substantially
reducedby completecessationofsmoking[4].Itisimportant
forallclinicianstomakearigorousefforttomotivatetobacco
users to cease tobacco use and to assist in their effort to quit
[4]. The Clinical Practice Guideline on Treating Tobacco Use
and Dependence published by the US Public Health Service
recommends to ask the patient if he or she uses tobacco,
advise him or her to quit, assess willingness to make a quit
attempt, assist him or her in making the quit attempt, and
arrange for follow-up contacts to prevent relapse [4]. In a
meta-analysis, it was shown that brief advice to quit smoking
from a clinician increases cessation rates by 30% [4].
The risk reduction after quitting smoking varies accord-
ing to the disease under consideration and also the popula-
tionconcerned.Itisfoundthatriskofcardiovasculardisease-
related death decreases precipitously at 6 months to 2 years.
In case of lung diseases and various cancers, the reduction
is less pronounced and more gradual. Improvements in lung
function can be discerned as soon as 1 year after cessation,
and with sustained abstinence, the age-related decline in
lung function returns to that of nonsmokers [5]. In case
of pregnant women, the risks of smoking-related pregnancy
complications are reduced to almost the nonsmoker level if
they quit during the first trimester [5]. The significant risk
reduction for cancers after stopping smoking can be seen in
5t o1 5y ea r s ,th o u ghth eri s ku s uall yd oe sn o ta p pea rt or ea c h
the level of never smokers [5].
2. Why Pharmacotherapy for the Treatment of
Nicotine Dependence?
Pharmacotherapyhasbeenofprovenbenefitintreatingnico-
tinedependence.Itisalsorecommendedthatpharmacother-
a p ys h o u l db eo ff e r e dt o“ a l ls m o k e r st r y i n gt oq u i t ,e x c e p t2 BioMed Research International
in the presence of special circumstances.” [4]. However,
with selected populations: those with medical contraindica-
tions, those smoking fewer than 10 cigarettes per day, preg-
nant/breastfeeding women, and adolescent smokers, special
considerationshouldbegivenbeforeusingpharmacotherapy
[4]. The most commonly used pharmacotherapy in case of
nicotine dependence is the nicotine replacement therapy
(NRT). The current clinical practice guideline recommends
thatNRTshouldbeusedbyallsmokerswhoaretryingtostop
smoking[6].NRTisgenerallyconsideredsafeinterventionto
general populations and higher-risk groups, including preg-
nant and breastfeeding women, adolescents, and smokers
with cardiovascular disease [7]. In a meta-analysis it was
foundthatcomparedwithplacebotwicethenumberofsmok-
ers sustained six months’ abstinence as a result of nicotine
replacement therapy [8]. The first-line pharmacotherapies
include nicotine replacement medications, bupropion and
varenicline which are all US FDA approved. Clonidine and
nortriptyline are suggested as the second line agents [4].
However, current pharmacological therapies available to
curb nicotine addiction offer only limited success [9]. One
reason for the low success is that many quitting attempts are
unplanned so that the most effective cessation aids may not
be used [8].
The main conclusions from the recently updated US
guidelines [4] for the treatment of tobacco dependence are
as follows.
( 1 )Th er o l eo fc o u n s e l i n ga sam o d a l i t yo ft r e a t m e n t
in nicotine dependent individuals is more important
than that thought previously.
(2) Vareniclineandnicotinepatchesincombinationwith
an oral product are possibly the most effective phar-
macological treatments.
(3) All smokers, irrespective of their intention to quit,
should be provided with the benefit of brief interven-
tions.
(4) There is a dearth of evidence to endorse the use
of medications by adolescents, pregnant smokers,
light smokers (<10 cigarettes per day), or smokeless
tobacco users.
3. Nicotine Replacement Therapy (NRT)
N i c o t i n e ,p o s s e s s i n ga na l k a l o i ds t r u c t u r e ,i sm a i n l yp r e s e n t
in the leaves of Solanaceae plants such as tobacco [9].
Nicotine is produces dependence by activating mesolimbic
dopaminergic reward system. Nicotine acts as an agonist of
neural nicotinic acetylcholine receptors (NAChRs), which
are found presynaptically in the central nervous system
a n dp o s t s y n a p t i c a l l yi nt h ea u t o n o m i cn e r v o u ss y s t e m[ 6].
With the increase in exposure to nicotine, NAChRs also
are increased, which results in nicotine tolerance. Thus,
those factors that decrease bioavailability of nicotine are
hypothesized to increase cravings for tobacco and decrease
thelikelihoodofcessationbecausemoreofthedrugisneeded
t oa c h i e v eag i v e nl e v e lo fd o p a m i n e .E x t r a p o l a t i n gt h i s
has led to the development of smoking cessation treatment
methods that emphasize nicotine replacement [6, 10].
The rationale of using nicotine replacement medication
for treating nicotine dependence is based on the theory of
harm reduction. The aim of the therapy is to relieve the
withdrawal symptoms related to nicotine use and thus help
the client to quit. Nicotine-containing medications make it
easier to abstain from tobacco by replacing the nicotine for-
merlyobtainedfromtobaccoandtherebyprovidingnicotine-
mediated neuropharmacologic effects [11]. The nicotine-
replacement medications reduce the withdrawal symptoms
or at least prominent ones, thus helping people to function
withoutcigarettes.Themedicationsmayalsoreducetherein-
forcingeffectsoftobacco-deliverednicotine.Finally,nicotine
medications may provide at least some effects for which
the patient previously relied on cigarettes, like sustaining
desirable mood and attention states, making it easier to
handle stressful or boring situations. However the evidence
f o rt h eo p e r a t i o no ft h e s em e c h a n i s m si sn o tc o n c l u s i v e .
Nonetheless, all of the approved nicotine replacement medi-
c a t i o n sh a v eb e e nf o u n dt ob es a f ea n de ff e c t i v ei ns m o k i n g
cessation [11].
The most common indication for NRT is to aid the
patients in abrupt cessation, but additional uses are also
licensedinsomecountries,suchasgradualreductiontoquit;
temporary abstinence, that is, for short periods of abstinence
where smoking is not allowed; and maintenance of reduction
[12]. NRT has also been investigated as an aid in reduction of
habit size of nicotine use among smokers not willing to quit.
In 2 meta-analyses, it was found that for smokers who are
u n w i l l i n gt os t o ps m o k i n gc o m p l e t e l yb u tw a n tt or e d u c e
their habit size the use of NR compared with placebo
increased the likelihood that they would make a cessation
attempt and that they succeeded more often with the cessa-
tion [4, 12].
NRTs are well tolerated and no life threatening adverse
events have been noted in studies. In a recent review, nausea
was found to be more common than placebo [8]. In another
r e v i e w ,i tw a sf o u n dt h a tN R Ti sa s s oc i a t e dw i t ha ni n c r e a s e d
risk of gastrointestinal complaints and insomnia. There were
also increased risk of skin irritation with the nicotine patch
andoropharyngealcomplaintswithorallyadministeredNRT
[7]. The most serious adverse events, consistently reported in
bothRCTsandobservationalstudies,wereheartpalpitations,
chest pains, and other arrhythmias including atrial fibril-
lation and myocardial infarction [7]. Unofficial guidelines
recommend cautious use of NRT in patients with known
cardiovascular disease in the absence of a physician [13].
4. Currently Available Nicotine
Replacement Therapies
Nicotine replacement medications should not be viewed
as standalone medications that make people stop smoking.
Reassurance and guidance from health professionals can be
criticaltoachieveandsustainabstinence.Sixtypesofnicotine
replacement products are on the market. These include
nicotine transdermal patch systems; nicotine nasal spray;BioMed Research International 3
and nicotine delivery through the oral mucosa including
gum, lozenge, sublingual tablet, and vapor inhaler [11]. Two-
milligram nicotine gum was first introduced in the United
States in February 1984 and was available to the consumers
onlywithprescription[6].Prescription-onlynicotinepatches
were introduced in 1992, followed by a nasal spray (1996),
inhaler (1997), and lozenge (2003) [6]. Common adverse
events seen with all NRT products include dizziness, nausea,
and headache.
5. Transdermal Nicotine Patches
Nicotine patches deliver nicotine through the skin at a
relatively steady rate [14]. Currently, four different types
of patches are available in the market with variation in
their design, pharmacokinetics, and duration of wear (i.e.,
24- and 16-hour wear). The dose adjustment may be done
depending upon the habit size of the patients. For example,
t h eN i c o D e r mC Qp a t c h( m a r k e t e di nt h eU n i t e dS t a t e s
by GlaxoSmithKline Consumer HealthCare) has 7, 14, and
21mg/day dose strengths and has been shown effective in
b o t h1 6 -a n d2 4 - h o u ru s e s .S m o k e r sw h ou s e1 0o rl e s s
c i g a r e t t e sp e rd a ya r ei n s t r u c t e dt ob e g i nw i t ht h e1 4 m g
patch, and those who smoke more than 10 per day are
instructed to start with 21mg [11]. Moreover, the NicoDerm
CQ and Habitrol systems are designed to be worn for 24
hours, but they can be removed after 16 hours and the
Nicotrol system is designed for 16 hours of wear (subjects
a r ei n s t r u c t e dt or e m o v et h ep a t c ha tb e d t i m e ) .U s eo ft h e
patch overnight may have advantage in relieving morning
c r a v i n gb u tm a yb em o r el i k e l yt oi n d u c es l e e pd i s t u r b a n c e s .
I nac l i n i c a lt r i a lw h i c hc o m p a r e dt h eN i c o D e r mC Qp a t c h
(21mg/24 hours) to the Nicotrol patch (15mg/16 hours), it
was found that the 21mg/24-hour patch yielded consistently
better control of craving, not only during the morning hours
but also throughout the day and over the 2-week period of
abstinence[15].However,increasingnicotineuptakebyusing
higher doses of transdermally absorbed nicotine has yielded
marginally higher success rates [16, 17].
Theadvantageofnicotinetransdermalpatchesoverother
preparations could be the ease to ensure compliance to
medication [2]. However, the patches may not be adequate
in relieving “acute” craving provoked by smoking-related
stimuli for all smokers [11]. A study tested the efficacy of
nicotine patches in combination with behavioral therapy for
the treatment of adolescent spit tobacco addiction. Tobacco
cessation rates were examined in three treatment groups:
au s u a lc a r eg r o u p ,ab e h a v i o ri n t e r v e n t i o nw i t hp l a c e b o
patchgroup,andabehaviorinterventionwithactivenicotine
p a t c h e sg r o u p .Th et o b a c c oc e s s a t i o nr a t ef o rt h eu s u a l
care group was 11.4%; for the placebo patch group, 25.0%;
and for active patch, 17.3%. The cessation rates for active
and placebo patches were not significantly different, proving
that behavioral intervention is twice as successful and that
nicotine patch did not offer additional improvement [18].
For breakthrough cravings not adequately controlled by
transdermal nicotine alone, acute therapies may be added.
6. Nicotine Gum
Nicotine gum, the first NRT, was first made available in
Europe in the early 1980s and in the US in 1984 [11]. The
gum is available in different flavors. The gum is available in
twodoses:2mgand4mg,deliveringapproximately1mgand
2mg, respectively. Users are instructed to use a piece of gum
every1-2hoursforthefirst6weeks,thentoreduceusetoone
p i e c ee v e r y2 – 4h o u r sf o r3w e e k s ,a n do n ep i e c ee v e r y4 –
8 hours for 3 weeks. In highly dependent smokers, the 4mg
g u mi ss u p e r i o rt ot h e2 m gg u m .S i n c ea b o u t5 0 %o ft h e
nicotine in gum is absorbed, a fixed schedule of 10 pieces
per day, a smoker receives about 10mg or 20mg of nicotine
p e rd a yu s i n gt h e2 m go r4 m gg u m ,r e s p e c t i v e l y .R o u n d
about50%ofthenicotineisabsorbedthroughbuccalmucosa
[19].Moreoverbecauseoftheslowabsorptionthroughbuccal
mucosa the highest arterial level of nicotine attained after
usinggumisrelativelylessthanattainedbysmokingcigarette.
It has also been seen that using acidic beverages prior to
the use of the gum interferes with its absorption; patients
should avoid acidic beverages (e.g., soda, coffee, and beer)
for 15 minutes before and during chewing gum [11]. Nicotine
gum chewing may cause jaw soreness; therefore, the smoker
s h o u l dc h e wt h eg u mt or e l e a s en i c o t i n e ,a n dt h e nm o v et h e
gumbetweenthecheekandgumforaminuteorso.Gumcan
also cause a mild burning sensation in the mouth and throat,
which may be undesirable.
7. Lozenge
Nicotine lozenge is available in the market in 1mg, 2mg,
and 4mg strengths [20]. The lozenge, unlike the gum, should
not be chewed and is considered both a benefit by some
patients and a weakness by others who enjoy gum chewing.
The amount of nicotine delivered per lozenge is higher than
that delivered by gum. Single dose studies demonstrated 8%
to10%highermaximalplasmaconcentrationand25%to27%
higher AUC values (area under concentration-time curve)
from lozenges compared with gums at both 2 and 4mg dose
levels [21].
8. Inhaler
This is a prescription medication in USA unlike gum.Th e
inhalerdeviceconsistsofamouthpieceandaplasticcartridge
which contains nicotine. Puffing the inhaler draws nicotine
through the mouthpiece into the mouth of the smoker. This
design particularly aimed at satisfying the hand-to-mouth
ritual of smoking [11]. The amount of nicotine delivered
through this device is related to the number of inhala-
tions. 80 deep puffs of the inhaler deliver 4mg of nicotine.
However, depth of inhalation is not a major determinant
of dosing [22]. Rather, the amount of nicotine through the
inhaler is temperature-dependent, with higher ambient air
temperaturesdeliveringlargeramountsofnicotineandlower
temperaturesdeliveringsmalleramounts[23].Theproductis
not a true inhaler; nicotine is not delivered to the bronchi or
lungs,butratherdepositedandabsorbedinthemouth,much
like nicotine gum [11]. Most people use between 6 and 164 BioMed Research International
cartridgesaday,andtherecommendeddurationoftreatment
is 3 months, after which patients may be weaned by gradual
reduction over the following 6–12 weeks.
9. Nasal Spray
Marketed as a prescription medication, the nasal spray is
designed to deliver nicotine more rapidly than other NRTs
and provides acute craving relief. Nicotine nasal spray is an
aqueous solution of nicotine in a 10mL spray bottle [23]. It
consistsofamultidosebottlewithapumpthatdelivers0.5mg
ofnicotineper50𝜇Lsquirt.Eachdoseconsistsoftwosquirts,
onetoeachnostril[23].Mostpatientsstartedwith1or2doses
per hour, which may be increased up to the maximum of 40
dosesperday.Nasalirritationisaknowndisadvantageofthis
method of NRT.
10. Sublingual Tablet
Anicotinetablethasbeendevelopedandismarketedinmany
EuropeancountriesbutnotyetintheUnitedStates.Thetablet
istobeheldunderthetongue,wherethenicotineinthetablet
is absorbed sublingually. The levels of nicotine obtained are
comparabletothegum[24].Itisrecommendedthatsmokers
u s et h ep r o d u c tf o ra tl e a s t1 2w e e k s ,a ft e rt h a tt h en u m b e ro f
tablets used is gradually tapered.
11. New Developments to Increase
the Efficacy of NRT
11.1. Combination of NR Products. Often, a smoker willing to
quit does not get the adequate replacement by a single form
of NRT. One of the commonly used methods to address this
i s s u ei st oc o m b i n ed i ff e r e n tf o r m so fN R Tp r o d u c t s ,m o r e
commonly, combining gum with a patch [12]. Evidence from
am e t a - a n a l y s i ss h o w st h a tc o m b i n i n gan i c o t i n ep a t c hw i t h
an oral form of NR was more effective than a single type of
NRT [25].
However, not only the dose received by the patients that
is important to reduce the craving and acute withdrawal
symptoms but also the rapidity of rise in blood nicotine
concentration following the dosing is vital. It has been found
that the nicotine nasal spray, though it delivers less nicotine
than nicotine gum, reduces craving faster than 4mg gums
d u et oi t sf a s t e s tu p t a k e[ 26].
Recently, some new formulations from NicoNovum
(Helsingborg, Sweden) have been tested: a mouth spray and
a small teabag-like pouch are to be fitted in under the upper
lip against the gum. In studies on smokers abstinent for 1
day, lozenge, mouth spray, and pouch were compared with
the Nicorette gum 4mg on craving, withdrawal symptoms,
a n dp r e f e r e n c ev a r i a b l e s .Th es t u d yp o p u l a t i o nt r i e da l lo f
t h ep r o d u c t s( m o u t hs p r a y ,l o z e n g ea n dp o u c h )w i t haw a s h -
out period in between. It was found that 2mg nicotine from
mouthspray (1mgper actuation)and4mgnicotinefromthe
pouch reduced craving more and faster than the 4mg gum
and were significantly more liked than the 4mg Nicorette
gum [12].
11.2. When and How to Initiate NRT? Though there is no
consensus, the patients are instructed to use one gum every
1 to 2 hours for the first 6 weeks and then to reduce use
to one piece every 2 to 4 hours for 3 weeks and one piece
e v e r y4t o8h o u r sf o r3w e e k s .S m o k e r sa r ea l s oa d v i s e dt o
use extra pieces between doses in response to episodes of
acute craving. Smokers who use less than 25 cigarettes per
dayareinstructedtousethe2mgdose,andthosewhosmoke
moreareinstructedtousethe4mgdose.Inhighlydependent
smokers, the 4mg is superior to the 2mg gum [11].
Usually patients are instructed to choose a quit date and
from that day onwards they are asked to use only NRT and
n oo t h e rt o b a c c op r o d u c t s .I nc a s eo fa n ya c u t ec r a v i n g,t h e y
a r ei n s t r u c t e dt ot a k ea d d i t i o n a ld o s a g ea sr e q u i r e d .U pt o
relativelyrecently,thelabellingofNRproductshasmandated
that they could only be used after cessation. Again, studies
a l s oe x p l o r e dt h ep o s s i b i l i t yo fs t a r t i n gN R Tb e f o r et h eq u i t
day. Four randomized control trials have tested precessation
familiarization with NRT. Many of these studies showed
improved long-term cessation rates for precessation use [27–
29]. A pragmatic randomized control trial on 1100 adult
smokers revealed that using NRT 2 weeks before the target
quit day was safe and well tolerated but offered no benefit
over usual care. However, in conjunction with previous
precessationtrialsthereappearstobeamoderatebenefit,but
not as large as that seen in most smaller trials [29].
Arecentmeta-analysisevaluatedtheincrementalefficacy
of starting nicotine patch treatment prior to cessation, com-
paredwiththecurrentregimenofstartingpatchtreatmenton
the target cessation day. It was documented that precessation
patch treatment produced a significant increase in cessation
rates at 6 months compared to current regimens starting
patch treatment on the day of cessation [30].
11.3. How Efficacious Are NRTs? Evidence for NRT effective-
nesscomesfrommorethan100placebo-controlledtrialswith
finalfollow-up6–12monthsafterthestartoftreatment.Meta-
analyses of these trials give odds ratios supporting active
treatment ranging from 1.7 to 2.3 according to NRT product
[31]. In one review, it was found that NRT improves cessation
ratesatoneyearbyapproximately70%[7].Inanotherreview,
it was shown that outcomes after only 6–12 months of follow-
up, as used in existing reviews and treatment guidelines, will
overestimate the lifetime benefit and cost-efficacy of NRT
by about 30% [32]. Because the long-term benefit of NRT
is modest, tobacco dependence treatment might be better
viewed as a chronic disorder, requiring repeated episodes of
treatment [32].
12. Bupropion
It was originally marketed as an antidepressant medication.
But subsequently it was also found to be helpful in man-
aging other conditions. Bupropion is chemically unrelated
to tricyclic antidepressants or selective serotonin reuptake
inhibitors (SSRIs). The mechanism of action as an antide-
pressant is poorly understood; presumably it involves dual
inhibition of dopamine and norepinephrine reuptake inBioMed Research International 5
both the mesolimbic dopaminergic system and the locus
ceruleus of the brain [33]. It has been hypothesized that the
increased levels of dopamine and norepinephrine in these
areas simulate the reward achieved when tobacco is used and
reduce withdrawal symptoms when tobacco use is stopped
[34]. Again the mechanism of action in smoking cessation
may be related to its effects on dopamine reward pathways or
toinhibitionofnicotinicacetylcholinereceptors[35].Itisalso
possible that bupropion acts by reducing some of the symp-
toms of nicotine withdrawal, which includes depression [11].
TheUSAClinicalPracticeGuidelinerecommendsBupropion
as a first line therapy for nicotine cessation [4].
Various studies have documented the role and efficacy
of bupropion in smoking cessation. Over a period of 2
weeks, 300mg of bupropion significantly reduced absti-
nence-associated increase in rated depression, difficulty in
concentrating and irritability and attenuated a decrease in
positive effect, relative to placebo [34]. The researchers also
f o u n dt h a tt h em e d i c a t i o nm i g h th a v eap o s i t i v ee ff e c t
on performance measures during the withdrawal period.
However, they did not notice any effects on craving, anxiety,
restlessness, or hunger. It has also been found that bupro-
pion combined with nicotine replacement medications may
increase rate of abstinence relative to bupropion alone [36].
The efficacy of bupropion is found to be related to the
dose used, mean plasma drug concentration, and the blood
concentration of the drug metabolites [37]. Smokers who
usedbupropionatadoseof100mg,150mg,or300mgdaily
were 1.42, 1.69, and 2.84 times more likely to quit smoking,
r e s pecti v e l y ,th a nth o sewh ou sedp l a c e bo[ 37]. Clinical trials
have also shown that the bupropion is equally efficacious in
both men and women [33]. A recent study has found that
those smokers who metabolised nicotine faster had relatively
better outcome. This study suggests that slow metabolisers
had equivalent cessation rates with placebo or bupropion
(32%) and fast metabolisers had low cessation rates with
placebo (10%) but significantly higher rates with bupropion
(34%) at the end of the 10-week treatment phase. However, at
the6-monthfollow-up,therelationshipbetweenthespeedof
metabolism and cessation remained similar, but differences
were no longer statistically significant [38]. In some earlier
clinical trials, a modest effect of bupropion SR on reducing
weight gain during the drug treatment phase was observed,
but no sustained effect was appreciated [33].
Threeformulationsofbupropionareavailable:immediate
release (taken three times daily), sustained release (taken
twice daily), and extended release (taken once daily). Mean
half-life of bupropion is about 12 hours, ranging from 8 to 40
hours. The 24-hour exposure occurring after administration
of the extended-release version of 300mg once daily is
equivalent to that provided by sustained release of 150mg
t w i c ed a i l y .C l i n i c a l l y ,t h i sp e r m i t st h ed r u gt ob et a k e no n c e
adayinthemorning.Therecommendedandmaximumdose
o fb u p r o p i o ni s3 0 0m g / d a y ,g i v e na s1 5 0m gt w i c ed a i l y[ 11].
Dry mouth and insomnia are the common adverse events
associated with bupropion use. Insomnia occurs in 30% to
45% of bupropion SR users at a dosage of 300mg/d. This
a d v e r s ee ff e c ti sf o u n dt ob er e l a t e dt od o s eu s e da n di sm o r e
common at higher doses [33]. The other minor side effects
are anxiety, nausea, and headache. There is also an increased
chance of seizures with the use of bupropion, the incidence
ranging from 0.1 to 0.4%. The seizure risk with bupropion is
higher for the immediate-release form of the drug when it is
given at doses of 450mg or more [33]. The usual length of
treatmentis6–12weeks,butbupropioncanbeusedsafelyfor
much longer [39].
13. Varenicline
Varenicline is an 𝗼4𝗽2 nicotinic receptor partial agonist for
smoking cessation. Varenicline was developed to have a
high affinity for 𝗼4𝗽2 nAChR in the mesolimbic dopamine
system and to act as a selective partial agonist of the 𝗼4𝗽2
nAChR. Binding at 𝗼4𝗽2 nAChR is considered to decrease
the craving for nicotine and to relieve the symptoms of
withdrawal (agonist effects). Additionally, blocking of nico-
tine’s binding at these receptors is hypothesized to reduce
nicotine-induced dopamine release and, consequently, its
rewarding/reinforcing effects (antagonist effects) [40].
Varenicline has already received US Food and Drug
Administration (FDA) approval for smoking cessation [41].
The recommended use of varenicline has been 0.5mg daily
for 3 days, 0.5mg b.i.d. for 4 days, and then 1mg b.i.d. for 11
weeks, and cessation is to occur during week two [42]. The
half-life of varenicline is 24 hours. Maximal plasma concen-
trationisachievedwithin3-4hoursafteradministration,and
asteady-stateconcentrationisreachedwithin4days.Theoral
bioavailability of this medication is not affected by food or
timeofadministration.Itcanbeadministeredoncedaily. But
intheclinicalsetting,vareniclinetreatmentcanbeoptimized
byreducingdosesinpatientswhoexperienceintolerableside
effects, increasing the dose in partial responders and pro-
vidinglong-termmaintenancetherapyforrelapseprevention
[43].
Varenicline has higher abstinence rates than placebo
and the alternative active treatments at the end of standard
regimen treatment periods. Significantly higher abstinence
rates were also found with varenicline in comparison to
b o t hp l a c e b oa n db u p r o p i o nS Ra tt h ee n do fa4 0 - w e e k
nontreatment follow-up period. Varenicline typically tripled
the abstinence rates compared with placebo. In addition,
varenicline reduced craving and withdrawal symptoms as
well as some of the positive experiences associated with
smoking to a greater extent than placebo, bupropion SR, and
nicotine replacement therapy (NRT) [44].
However,despiteinitialencouragingresults,theinterpre-
tation of these studies should be judged by limitations. Many
of these studies were sponsored by pharmaceutical compa-
nies. The adverse effect profile of varenicline included nearly
30% of participants reporting nausea, significantly higher
proportion of patients reporting abnormal dreams [41].
Moreover, varenicline is suspected to exacerbate depressed-
m o o d ,a sw e l la se r r a t i ca n dp o s s i b l es u i c i d a lb e h a v i o r .
In 2008, the FDA issued a warning linking varenicline to
serious neuropsychiatric symptoms emphasizing the need
for alternate therapy, such as immunopharmacotherapy, to6 BioMed Research International
a i ds m o k i n gc e s s a t i o n[ 8]. A meta-analysis of 14 double-
blind randomized controlled trials involving 8216 partic-
ipants has shown that varenicline was associated with a
significantly increased risk of serious adverse cardiovascular
events compared with placebo (1.06% in varenicline group
versus0.82%inplacebogroup)[45].Still,vareniclineappears
to be a promising medication in management of nicotine
dependence.
14. Other Medications for Treating
Nicotine Dependence
14.1.Nortriptyline. AlthoughtheU .S.FoodandDrugAdmin-
istration (FDA) has not approved nortriptyline for use in
smokingcessation,theTobaccoUseandDependenceClinical
P r a c t i c eG u i d e l i n eP a n e lo ft h eU . S .P u b l i cH e a l t hS e r v i c e
recommends it as a second-choice medicine for this use [4].
Six placebo controlled trials have shown that nortriptyline
doubles the quit rate as compared to placebo and the efficacy
did not appear to be related to its antidepressant action [46].
14.2. Clonidine. Clonidine is an 𝗼 noradrenergic agonist that
suppresses sympathetic activity and has been used for hyper-
tension and to reduce withdrawal symptoms associated with
misuse of alcohol and opiates. Both in its oral and low dose
patch formulation, clonidine increased smoking cessation in
eight out of nine trials, but the drug is associated with serious
side effects, including sedation and postural hypotension.
Clonidine is therefore probably best reserved for smokers
w h oc a n n o to rd on o tw i s ht ou s eN R T ,b u p r o p i o n ,o r
nortriptyline [47].
14.3. Nicotine Vaccines. Efforts have been made to produce
antibodies against the nicotine molecule that prevents the
drug from reaching neural receptors that produce the effects
normally associated with smoking.
A significant number of nicotine haptens have been
reported.Additionally,varioustypesofdeliveryvehicleshave
been used which range from traditional carrier proteins
such as KLH, recombinant cholera toxin B subunit, and
pseudomonas exoprotein A to a 19-residue conformationally
biased peptide that eliminates the need for external adjuvant.
Finally, virus-like particles derived from Qb bacteriophage
have been used [9].
The vaccine stimulates the immune system to pro-
duce antibodies against nicotine, and the nicotine-antibody
molecules are too large to pass from the blood into the brain
[48]. Theoretically, by eliminating the amount of nicotine
reaching brain, one would reduce the reinforcing property
of tobacco smoking, eventually leading to extinction of the
behavior. However, since the amount of nicotine reaching
brain is reduced rather than completely eliminated, there
are possibilities that some smokers would actually increase
tobaccoconsumption,atleastintheshortterm,toachievethe
levels of nicotine normally obtained during smoking. Results
also suggest that a nicotine vaccine would be useful as a
relapse prevention treatment [11].
Preclinical studies of short- and long-term administra-
tion of nicotine found that one of the nicotine vaccines
reduced the distribution of nicotine into the brain in rats
by up to 65% [48]. There are at least three companies in
earlyclinicaldevelopmentofanantinicotinevaccine:Xenova
(TA-NIC), Nabi (NicVAX), and Cytos (Nicotine-Qbeta) [47].
Active immunization was done with 2 to 6 doses in a period
o f2t o4w e e k sp l u sal a t e rb o o s tf o rN i c V A Xa n dT A - N I C .
The serum antibody levels increased after each subsequent
dose and were maintained over a couple of months, however,
only via subsequent booster dosage. Phase I results for all
t h r e ev a c c i n e sr e v e a l e dt h a tt h ef o r m u l a t i o n sw e r es a f ea n d
well tolerated with only mild local and systemic reactions
that subsided withoutmedicalintervention.However, results
fromlargescalephaseIItrialshavebeenreleasedforN icV AX
and NicQb showing limited efficacy obtained to date [9].
In another randomized controlled trial, the most prevalent
local adverse event was pain at the injection site and the
most frequent systemic adverse event was transient flu-like
symptoms which were self-limiting [49].
It has been found in a clinical study that was designed
to test safety in an escalating dose design demonstrated that
more subjects with high antibody responses quit smoking
during the trial than those with lower antibody responses
[50]. It is also worth mentioning here that several authors
have noted that vaccines might be used as a prevention
technique in youths that do not smoke or are experimenting
[51].
14.4. Rimonabant. Rimonabant, a selective type 1 cannabi-
noid receptor (CB1) antagonist, may assist smoking cessation
by restoring the balance of the endocannabinoid system,
which can be disrupted by prolonged use of nicotine [52].
During treatment, overweight or obese smokers tended to
lose weight, while normal weight smokers did not. Early in
2006, the FDA issued a nonapprovable letter for the smoking
cessation indication; thus, further studies may be required
before the FDA will reconsider approval of rimonabant for
smoking cessation [52]. Several countries have placed legal
restrictions on the compound.
15. Conclusion
Nicotine dependence syndrome is a burning problem of the
present world considering its impact on health and morbid-
ity. Several medications have been tried including age old
nicotine replacement therapies, bupropion, and varenicline.
Recent endeavor in this regard is a nicotine vaccine which is
yet to gain approval for routine application.
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